5-Bromo-2-(oxetan-3-yloxy)pyrimidine | 1207174-86-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-Bromo-2-(oxetan-3-yloxy)pyrimidine
• 英文别名: 5-bromo-2-(oxetan-3-yloxy)pyrimidine
• CAS: 1207174-86-4
• 化学式: C₇H₇BrN₂O₂
• 分子量: 231.05
• InChiKey: KJZWINUOMLGAPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  44.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Indolin-2-one derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US10457667B2

  公开（公告）日：2019-10-29

  The present invention is concerned with indolin-2-one derivatives of general formula wherein A is phenyl or a six membered heteroaryl group, containing one or two N atoms, selected from or the oxygen atom may form together with two neighboring carbon atoms from the group A an additional fused ring, selected from R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen or oxetanyl; R2 is hydrogen, lower alkyl lower alkoxy, halogen or cycloalkyl; --- the dotted line is nothing or may be —CH2—; as well as with a pharmaceutically acceptable salt thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co morbid epilepsy.

  本发明涉及通式如下的吲哚啉-2-酮衍生物 式中 A 是苯基或含有一个或两个 N 原子的六成员杂芳基，选自 或氧原子可与 A 组中两个相邻的碳原子共同形成一个额外的融合环，该环可选自以下组别 R1 是氢、低级烷基、被卤素取代的低级烷基或氧杂环丁烷基； R2 是氢、低级烷基、低级烷氧基、卤素或环烷基； 以及其药学上可接受的盐、外消旋混合物或其相应的对映体和/或光学异构体和/或立体异构体。 这些化合物可用于治疗与精神分裂症的阳性（精神病）和阴性症状相关的中枢神经系统疾病、药物滥用、酒精和药物成瘾、强迫症、认知障碍、双相情感障碍、情绪障碍、重度抑郁症、抗药性抑郁症、焦虑症、阿尔茨海默病、自闭症、帕金森病、慢性疼痛、边缘型人格障碍、神经退行性疾病、睡眠障碍、慢性疼痛、慢性髓鞘病、神经性瘫痪、神经性瘫痪、神经性瘫痪、神经性瘫痪、神经性瘫痪、神经性瘫痪、神经性瘫痪、神经性瘫痪、神经性瘫痪、神经性瘫痪、神经性瘫痪、神经性瘫痪、神经性瘫痪、神经退行性疾病、睡眠障碍、慢性疲劳综合征、僵硬症、炎症性疾病、哮喘、亨廷顿氏病、多动症、肌萎缩侧索硬化症、对关节炎的影响、自身免疫性疾病、病毒和真菌感染、心血管疾病、眼科和炎症性视网膜疾病以及平衡问题、癫痫和伴有癫痫的神经发育障碍。
• INDOLIN-2-ONE DERIVATIVES FOR USE IN THE TREATMENT OF CNS AND RELATED DISORDERS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3371169B1

  公开（公告）日：2019-07-17
• INDOLIN-2-ONE DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20180251451A1

  公开（公告）日：2018-09-06

  The present invention is concerned with indolin-2-one derivatives of general formula wherein A is phenyl or a six membered heteroaryl group, containing one or two N atoms, selected from or the oxygen atom may form together with two neighboring carbon atoms from the group A an additional fused ring, selected from R 1 is hydrogen, lower alkyl, lower alkyl substituted by halogen or oxetanyl; R 2 is hydrogen, lower alkyl lower alkoxy, halogen or cycloalkyl; --- the dotted line is nothing or may be —CH 2 —; as well as with a pharmaceutically acceptable salt thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co morbid epilepsy.